We are pleased to share an article in Springer Nature written by a team of independent authors, including Dr. Gordana Tonkovic, Ergomed CRO President.
The article, titled “Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19”, describes an observational cohort study that began at the start of the pandemic in order to investigate siltuximab as a potential treatment for patients with SARS-CoV-2 pneumonia, hyper inflammation, and respiratory failure. The preliminary study found that reduction of IL-8 and PTX3 levels on day 4 following siltuximab treatment is associated with improved survival and ventilatory outcomes in patients hospitalized for COVID-19. Further to this, a randomized clinical trial would be informative to confirm the efficacy and safety of this IL-6–neutralizing monoclonal antibody in the treatment of patients with viral acute respiratory distress syndrome.
Read the article here: https://www.nature.com/articles/s41375-021-01299-x
To download the article, click here.
For more information, please contact us.
